Closing of Over-Allotment Options, Receiving Orphan Drug Designations, Release of Clinical Data, and Obtaining Important Patents

Closing of Over-Allotment Options, Receiving Orphan Drug Designations, Release of Clinical Data, and Obtaining Important Patents - Research Report on Galena,                     Zalicus, Infinity, Stemline and Insmed  Editor Note: For more information about this release, please scroll to bottom  PR Newswire  NEW YORK, November 5, 2013  NEW YORK, November 5, 2013 /PRNewswire/ --  Today, Analysts' Corner announced new research reports highlighting Galena Biopharma, Inc. (NASDAQ: GALE), Zalicus Inc. (NASDAQ: ZLCS), Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), Stemline Therapeutics, Inc. (NASDAQ: STML) and Insmed Incorporated (NASDAQ: INSM). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.  Galena Biopharma, Inc. Research Report  On September 23, 2013, Galena Biopharma, Inc. (Galena) announced the closing of the exercise in full of the underwriters' over-allotment option to purchase an additional 2.6 million shares of common stock of Galena. The Company reported that the additional gross proceeds to Galena as a result of the exercise of the option with respect to the shares are approximately $5.2 million. The net proceeds to Galena from the offering, including from the exercise in full of the over-allotment options, are expected to be approximately $37.6 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by Galena. The Company stated that it intends to use the net proceeds of the offering for the commercialization of its first commercial product, Abstral® (fentanyl) Sublingual Tablets, other clinical trials of its product candidates, and general corporate purposes. The Full Research Report on Galena Biopharma, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/cad6_GALE]  --  Zalicus Inc. Research Report  On September 27, 2013, Zalicus Inc. (Zalicus) announced that Z160, its first-in-class, oral, state-dependent, selective N-type calcium channel (Cav 2.2) modulator in development for chronic neuropathic pain has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the management of postherpetic neuralgia. According to the Company, Postherpetic neuralgia (PHN) is a painful neuropathic condition resulting from an outbreak of the herpes zoster virus, otherwise known as shingles. Mark H.N. Corrigan, MD, President and CEO of Zalicus commented, "The FDA's designation of Z160 as having orphan drug status is an important milestone for Zalicus as we continue the clinical development work required for potential FDA approval of Z160." The Full Research Report on Zalicus Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/cbb5_ZLCS]  --  Infinity Pharmaceuticals, Inc. Research Report  On September 25, 2013, Infinity Pharmaceuticals, Inc. (Infinity) announced topline data from its Phase 2 study of retaspimycin hydrochloride (HCl), a potent and selective heat shock protein 90 (Hsp90) inhibitor, in patients with non-small cell lung cancer (NSCLC) who had a history of smoking. Infinity reported that retaspimycin HCl did not meet its pre-specified efficacy endpoints for demonstrating an improvement in overall survival in the total patient population or in patients with squamous cell carcinoma. "We appreciate the support of the patients and caregivers who participated in this trial," stated Julian Adams, Ph.D., President of Research and Development at Infinity. "We will now focus our clinical research and development effort on IPI-145, our lead PI3K-delta, gamma inhibitor, for which we have encouraging data in patients with life-threatening hematologic malignancies." The Full Research Report on Infinity Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/3862_INFI]  --  Stemline Therapeutics, Inc. Research Report  On September 25, 2013, Stemline Therapeutics, Inc. (Stemline Therapeutics) announced that SL-401, a Clinical-Stage Targeted Therapy, has shown preclinical activity in an additional hematologic cancer indication, chronic myeloid leukemia. The Company informed that SL-401 is a novel therapeutic targeting the interleukin-3 receptor (IL-3R) that is overexpressed on the CSCs and tumor bulk of a wide range of hematologic cancers, which is now entering pivotal clinical trial programs in blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukemia (AML), as well as clinical evaluations in several other hematologic malignancies. The Full Research Report on Stemline Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/5155_STML]  --  Insmed Incorporated Research Report  On September 11, 2013, Insmed Inc. (Insmed) announced two important patent allowances in the U.S. and Europe that will strengthen the Company's global patent portfolio. Insmed stated that it is focused on the development and commercialization of ARIKACE® (liposomal amikacin for inhalation) for at least two identified orphan patient populations: cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections and patients with non-tuberculous mycobacteria (NTM) lung infections. Commenting on the patent allowances, Will Lewis, President and CEO of Insmed said, "These new patent allowances are a credit to our technology development team and demonstrate the inventiveness and utility of our approach to treating serious and oftentimes life-threatening lung diseases. As we move toward potential marketing approval and commercialization of ARIKACE to treat Pseudomonas aeruginosa in CF patients in Europe and Canada, and continue the clinical development of our liposomal amikacin for inhalation to treat NTM in the U.S., these new patent allowances provide additional protection for this valuable asset. We are pursuing a broad intellectual property strategy that provides the foundation to achieve our global clinical and commercial objectives and protects shareholder value." The Full Research Report on Insmed Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/9c5b_INSM]  ----  EDITOR NOTES:  1.This is not company news. We are an independent source and our views do     not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts     basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are     only human and are prone to make mistakes. If you notice any errors or     omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to     increase awareness for mentioned companies to our subscriber base and the     investing public. 4.If you wish to have your company covered in more detail by our team, or     wish to learn more about our services, please contact us at     pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at     compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your     company? Send us a full investors' package to     research@EquityNewsNetwork.com for consideration.  COMPLIANCE PROCEDURE  Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.  NOT FINANCIAL ADVICE  Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.  NO WARRANTY OR LIABILITY ASSUMED  Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.  CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.  SOURCE Analysts' Corner  Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)  
Press spacebar to pause and continue. Press esc to stop.